Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays site revision v3.8.1 instead of v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-18T01:58:00.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The ARCADIA bladder cancer study record is available, describing its phase 2 trial of cabozantinib plus durvalumab, participant criteria, outcome measures, and recruiting site in Milan.
    Difference
    56%
    Check dated 2026-11-11T01:10:16.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The site footer now identifies the release as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-03T23:26:16.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    A notice about NIH website changes appears above the 403 error page, and the site revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:06:19.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1; the page otherwise remains a 403 Forbidden error page.
    Difference
    0.2%
    Check dated 2026-10-07T00:24:26.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The study page now returns a 403 Forbidden error, replacing the previously visible trial details with an access-denied message. This blocks access to core information about the trial, including its status, eligibility, locations, and contacts.
    Difference
    20%
    Check dated 2026-09-22T23:21:18.000Z thumbnail image

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.